Ambenonium chloride
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 573777

CAS#: 115-79-7 (chloride)

Description: Ambenonium Chloride is a quaternary ammonium compound with parasympathomimetic activity. It is a cholinesterase inhibitor used in the management of myasthenia gravis. Myasthenia gravis occurs when the body produces antibodies against acetylcholine receptors, and thus inhibits signal transmission across the myoneural junction. Ambenonium chloride is a rapid indirect-acting cholinergic agonist that reversibly blocks the activity of acetylcholinesterase, thereby prevents acetylcholine hydrolysis and prolonging its activity on nicotinic receptors at the neuromuscular junction.


Chemical Structure

img
Ambenonium chloride
CAS# 115-79-7 (chloride)

Theoretical Analysis

MedKoo Cat#: 573777
Name: Ambenonium chloride
CAS#: 115-79-7 (chloride)
Chemical Formula: C28H42Cl4N4O2
Exact Mass: 606.21
Molecular Weight: 608.470
Elemental Analysis: C, 55.27; H, 6.96; Cl, 23.30; N, 9.21; O, 5.26

Price and Availability

Size Price Availability Quantity
10mg USD 450 2 Weeks
Bulk inquiry

Related CAS #: 52022-31-8 (chloride hydrate)   115-79-7 (chloride)   7648-98-8 (cation)    

Synonym: AI3-22370, Ambenonium chloride; Ambenonium dichloride; Ambestigmin chloride; Misuran; Mysuran; Mysuran chloride; Mytelase; Mytelase chloride; Oxamizil; Oxazil; Oxazyl; Win 8077; Win-8077; Win8077;

IUPAC/Chemical Name: Ammonium, (oxalylbis(iminoethylene))bis((o-chlorobenzyl)diethyl-, dichloride

InChi Key: DXUUXWKFVDVHIK-UHFFFAOYSA-N

InChi Code: 1S/C28H40Cl2N4O2.2ClH/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30;;/h9-16H,5-8,17-22H2,1-4H3;2*1H

SMILES Code: CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc2ccccc2Cl.[Cl-].[Cl-]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 608.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gilhus NE, Andersen H, Andersen LK, Boldingh M, Laakso S, Leopoldsdottir MO, Madsen S, Piehl F, Popperud TH, Punga AR, Schirakow L, Vissing J. Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment. Eur J Neurol. 2024 Feb 6:e16229. doi: 10.1111/ene.16229. Epub ahead of print. PMID: 38321574.


2: Sumiji T, Sugano K. Food and bile micelle binding of quaternary ammonium compounds. ADMET DMPK. 2023 Sep 15;11(3):409-417. doi: 10.5599/admet.2023. PMID: 37829320; PMCID: PMC10567067.


3: Zhang Q, Lv J, Xia J, Wang L, Qu G, Yang Y, Yang Y, Liu S. Rapid detection of carbamate nerve agent analogues using dually functionalized gold nanoclusters. Anal Bioanal Chem. 2023 Jul;415(16):3275-3284. doi: 10.1007/s00216-023-04707-6. Epub 2023 Jun 2. PMID: 37266687.


4: Gomes IS, Santana CA, Marcolino LS, Lima LHF, Melo-Minardi RC, Dias RS, de Paula SO, Silveira SA. Computational prediction of potential inhibitors for SARS-COV-2 main protease based on machine learning, docking, MM-PBSA calculations, and metadynamics. PLoS One. 2022 Apr 22;17(4):e0267471. doi: 10.1371/journal.pone.0267471. PMID: 35452494; PMCID: PMC9032443.


5: Sobieszczuk E, Napiórkowski Ł, Szczudlik P, Kostera-Pruszczyk A. Myasthenia gravis-treatment and severity in nationwide cohort. Acta Neurol Scand. 2022 Apr;145(4):471-478. doi: 10.1111/ane.13576. Epub 2022 Jan 4. PMID: 34981830.


6: Li S, Zhao J, Huang R, Travers J, Klumpp-Thomas C, Yu W, MacKerell AD Jr, Sakamuru S, Ooka M, Xue F, Sipes NS, Hsieh JH, Ryan K, Simeonov A, Santillo MF, Xia M. Profiling the Tox21 Chemical Collection for Acetylcholinesterase Inhibition. Environ Health Perspect. 2021 Apr;129(4):47008. doi: 10.1289/EHP6993. Epub 2021 Apr 12. PMID: 33844597; PMCID: PMC8041433.


7: Sobieszczuk E, Napiórkowski Ł, Szczudlik P, Kostera-Pruszczyk A. Myasthenia Gravis in Poland: National Healthcare Database Epidemiological Study. Neuroepidemiology. 2021 Feb 19:1-8. doi: 10.1159/000512973. Epub ahead of print. PMID: 33611318.


8: Obara K, Chino D, Tanaka Y. Long-Lasting Inhibitory Effects of Distigmine on Recombinant Human Acetylcholinesterase Activity. Biol Pharm Bull. 2017;40(10):1739-1746. doi: 10.1248/bpb.b17-00351. PMID: 28966245.


9: Obara K, Ogawa T, Chino D, Tanaka Y. The Long-Lasting Enhancing Effect of Distigmine on Acetylcholine-Induced Contraction of Guinea Pig Detrusor Smooth Muscle Correlates with Its Anticholinesterase Activity. Biol Pharm Bull. 2017;40(7):1092-1100. doi: 10.1248/bpb.b17-00175. PMID: 28674252.


10: Mamaligas AA, Ford CP. Spontaneous Synaptic Activation of Muscarinic Receptors by Striatal Cholinergic Neuron Firing. Neuron. 2016 Aug 3;91(3):574-86. doi: 10.1016/j.neuron.2016.06.021. Epub 2016 Jun 30. PMID: 27373830; PMCID: PMC5234077.


11: Zuo ZX, Wang YJ, Liu L, Wang Y, Mei SH, Feng ZH, Wang M, Li XY. Huperzine A Alleviates Mechanical Allodynia but Not Spontaneous Pain via Muscarinic Acetylcholine Receptors in Mice. Neural Plast. 2015;2015:453170. doi: 10.1155/2015/453170. Epub 2015 Dec 1. PMID: 26697233; PMCID: PMC4678084.


12: Draczkowski P, Tomaszuk A, Halczuk P, Strzemski M, Matosiuk D, Jozwiak K. Determination of affinity and efficacy of acetylcholinesterase inhibitors using isothermal titration calorimetry. Biochim Biophys Acta. 2016 May;1860(5):967-974. doi: 10.1016/j.bbagen.2015.11.006. Epub 2015 Nov 14. PMID: 26586471.


13: Petrov KA, Girard E, Nikitashina AD, Colasante C, Bernard V, Nurullin L, Leroy J, Samigullin D, Colak O, Nikolsky E, Plaud B, Krejci E. Schwann cells sense and control acetylcholine spillover at the neuromuscular junction by α7 nicotinic receptors and butyrylcholinesterase. J Neurosci. 2014 Sep 3;34(36):11870-83. doi: 10.1523/JNEUROSCI.0329-14.2014. PMID: 25186736; PMCID: PMC6608466.


14: Nishikawa A, Mori-Yoshimura M, Okamoto T, Oya Y, Nakata T, Ohno K, Murata M. [Beneficial effects of 3,4-diaminopyridine in a 26-year-old woman with DOK7 congenital myasthenic syndrome who was originally diagnosed with facioscapulohumeral dystrophy]. Rinsho Shinkeigaku. 2014;54(7):561-4. Japanese. doi: 10.5692/clinicalneurol.54.561. PMID: 25087557.


15: Komloova M, Horova A, Hrabinova M, Jun D, Dolezal M, Vinsova J, Kuca K, Musilek K. Preparation, in vitro evaluation and molecular modelling of pyridinium-quinolinium/isoquinolinium non-symmetrical bisquaternary cholinesterase inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6663-6. doi: 10.1016/j.bmcl.2013.10.043. Epub 2013 Oct 31. PMID: 24220173.


16: Yudin MA, Ivanov IM, Nikiforov AS, Kornyukhina TM, Tyunin MA. Use of inclusion complex of cyclodextrin with ambenonium to improve the treatment of anticholinesterase poisoning. Bull Exp Biol Med. 2013 Jun;155(2):218-20. doi: 10.1007/s10517-013-2117-1. PMID: 24130994.


17: Perez XA, McIntosh JM, Quik M. Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbens. J Neurochem. 2013 Dec;127(6):762-71. doi: 10.1111/jnc.12442. Epub 2013 Oct 13. PMID: 23992036; PMCID: PMC3859710.


18: Komloova M, Musilek K, Horova A, Holas O, Dohnal V, Gunn-Moore F, Kuca K. Preparation, in vitro screening and molecular modelling of symmetrical bis- quinolinium cholinesterase inhibitors--implications for early myasthenia gravis treatment. Bioorg Med Chem Lett. 2011 Apr 15;21(8):2505-9. doi: 10.1016/j.bmcl.2011.02.047. Epub 2011 Feb 21. PMID: 21397501.


19: Musilek K, Komloova M, Holas O, Hrabinova M, Pohanka M, Dohnal V, Nachon F, Dolezal M, Kuca K. Preparation and in vitro screening of symmetrical bis- isoquinolinium cholinesterase inhibitors bearing various connecting linkage-- implications for early Myasthenia gravis treatment. Eur J Med Chem. 2011 Feb;46(2):811-8. doi: 10.1016/j.ejmech.2010.12.011. Epub 2010 Dec 21. PMID: 21236521.


20: Kaneda H, Saito Y, Saito T, Maniwa T, Minami K, Kusaka H, Imamura H. Preoperative steroid therapy stabilizes postoperative respiratory conditions in myasthenia gravis. Gen Thorac Cardiovasc Surg. 2008 Mar;56(3):114-8. doi: 10.1007/s11748-007-0195-6. Epub 2008 Mar 14. PMID: 18340510.